Table 1 Outcome measures for the trial

Primary

Laboratory-confirmed Aedes-borne disease

2–15-year-olds at enrollment

Laboratory-confirmed (virologically [RT-PCR testing of acute samples] or serologically [IgM and IgG ELISA testing of paired acute and convalescent samples]) symptomatic DENV, CHIKV, or ZIKV

Secondary

Laboratory-confirmed Aedes-borne infection

2–15-year-olds at enrollment

Laboratory-confirmed (serologically, [IgG ELISA and neutralization testing of annual surveillance samples]) DENV, CHIKV, or ZIKV infection. A FRNT50 for one DENV serotype ≥ 4-fold the FRNT50 to the other 3 serotypes is considered DENV mono-immune seroconversion

Secondary

Aedes aegypti infection with Aedes-borne viruses

Female Ae. aegypti collected in central 3 × 3 blocks of each cluster

Ae. aegypti mosquito infection rates with DENV, CHIKV, and ZIKV (assessed by RT-PCR) from 10% of households

Secondary

Aedes aegypti infestation

Ae. aegypti collected in central 3 × 3 blocks of each cluster

Ae. aegypti indoor entomological indices (adult presence and abundance, female presence and abundance, blood-fed female and abundance) from 10% of households

Secondary

Community acceptability of TIRS

Head of household in clusters receiving TIRS

Households receiving the intervention will be asked about their response and issues with TIRS. Conducted on same houses where entomology occurs.

Secondary

Community impact of TIRS

All ages

Number of symptomatic ABV cases reported to the passive surveillance system, including children and adults, distributed in treatment and control clusters

Secondary

Safety profile

All houses in 5 × 5 block treatment clusters

Percentage of households receiving the intervention that had evidence of a reaction to the insecticide (assessed and confirmed by study doctors). All sprayed households are eligible.